Biotech partnering
On these webpages, start-up companies can locate contacts within the vfa member companies for potential collaboration as well as informative guidelines regarding the information an interested start-up company should prepare for its initial contact with a research-based pharmaceutical company. Through collaborations and strategic alliances, both partners can contribute their individual strong points.
-
Contact
-
Ulrich Huetter
Licensing & Business Development
Telephone: +49 621 594-2408
Telefax: +49 621 594-1797
-
Scope of collaboration
-
-
Offer
-
- Distribution in clinic and practice
- Marketing
- Support regarding regulatory affairs from phase III
-
Request
-
- Products for clinic and practice of phase III
-
Contact
-
Michael Danzl
General Manager
Telephone: +49 761 4564-11
Telefax: +49 761 4564-45
-
Scope of collaboration
-
- Product
- Licence
- Distribution
-
Offer
-
-
Request
-
- Products of phase II - III
- HT-Screening
- Chemical Libraries
- Formulation development
- Small Molecules
- Target Search
-
Indications
-
- Pulmonary diseases
- Cardiovascular diseases
- Oncology
- Gastroenterology/metabolism
-
Contact
-
Dr. Karl-Heinz Grajer
Executive Managing Director
Telephone: +49 89 149096-1600
Telefax: +49 89 149096-2600
-
Scope of collaboration
-
- Product
- Technology
- License
- Distribution
- Shareholding
-
Request
-
- Product development phase I - III
- Angiogenesis
- Gene Therapy
- Cytokines
- Cytotoxic agents
- Functional genomics
- Haematology
- Neurology
- Nephrology
- Oncology
- Small molecules
-
Indications
-
- Nephrology
- Oncology
- Orphan diseases
- Further osteology
-
Contact
-
Dr. Günter Auerbach
Head Business Operations
Telephone: +49 941 920 130
Telefax: +49 941 920 1329
-
Scope of collaboration
-
- Licence
- Distribution
- Stategic alliances
- Further
-
Offer
-
- Product development
- Clinical development
- Licensing
-
Request
-
- Products
- Therapeutics/diagnostics from pre-clinical to phase III
- Drug discovery
- Cell therapy
- Cytokines
- Small molecuels
-
Indications
-
-
Scope of collaboration
-
- Product
- Licence
- Distribution
- Strategic alliances
-
Offer
-
- Licensing
- Marketing & Distribution
-
Request
-
- Products
- Therapeutics/diagnostics from phase III
-
Indications
-
- Anti-infective
- Dermatology
- Orphan diseases
-
Contact
-
Dr. Mark Wolters
Division Bayer Schering Pharma
Telephone: +49 30 468-12559
Telefax: +49 30 468-18110
-
Scope of collaboration
-
- Project
- Technology
- Licence
- Strategic alliances
- Shareholding
-
Offer
-
- Marketing & Distribution
- Product development
- Medical Chemistry
- PK/PD
- Toxicology
- Formulation development
- Production
- Production of recombinant proteins
-
Request
-
- Therapeutics with "proof of concept (POC)"
- Chemical libraries
- Small molecules
-
Indications
-
- Antibacterial
- Cardiocasvular risk management
- Oncology
- Urologic application
- Erectile dysfunction (ED)
- Benign prostata hyperplasia (BPH)
- Incontinence
- Diabetes
-
Contact
-
Wyatt Gotbetter
Director, New Product Commercialization
Telephone: +49 89 99617-108
Telefax: +49 89 99617-199
-
Scope of collaboration
-
- Licence
- Distribution
- Strategic alliances
-
Indications
-
- Neurology
- Oncology
- Dermatology
- Immunology
-
Contact
-
Dr. Frank Plöger
Head Development
Telephone: +49 6221 538358
Telefax: +49 6221 53834458
-
Scope of collaboration
-
- Development
- Project
- Technology
- Product
- Licence
- Strategic alliances
-
Offer
-
- Product development
- Formulation development
- Licensing
- Further:
- Cell culture
- Bio-assays
- Analytic
-
Indications
-
- Alzheimer´s disease
- Dermatology
- Musculoskeletal disorders
- Oncology
- Urology
- CNS
-
Contact
-
Gerald Feger
Head Business Development
Telephone: +49 89 12142-460
Telefax: +49 89 12142-519
-
Scope of collaboration
-
-
Indications
-
- Cardiovascular diseases
- Oncology
- CNS
- Anti-infective agents/HIV
- Metabolism
-
Scope of collaboration
-
- Development
- Project
- Technology
- Product
- Licence
- Distribution
- Strategic alliances
-
Offer
-
- Product development
- Formulation development
- Production
- Clinical development
- Regulatory affairs
- License
-
Request
-
- Therapeutics/diagnostics from pre-clinical phase I - III
- Production of recombinant proteins
- all biopharmaceutical products on the basis of mammal cell cultures + microorganism
- HT-Screening
- Angiogenesis
- Cytotoxic Agents
- Cytokines
- Chemical Libraries
- Gene Therapy
- Formulierungsentwicklung
- Functional Genomics
- Small Molecules
- Target Search
- Pharmacogenetics
-
Indications
-
- Anti-infective agents/HIV
- Pulmonary diseases
- Cardiovascular diseases
- Immunology/allergology
- Nephrology
- Oncology
- Pain
- Urology
- Gastroenterology/metabolism
- CNS
-
Contact
-
Isabel Feys
Partner Accreditation
Telephone: +49 30 2639288 15
Telefax: +49 30 2639288 20
-
Scope of collaboration
-
- Research project
- Development project
- Technology
- Product
- Licence
- Strategic alliances
-
Offer
-
- Product sale
- Marketing & distribution
-
Request
-
- Products
- Therapeutics/diagnostics from pre-clinical to phase III
- Drug discovery
- Angiogenesis
- Cell cycling
- Cell therapy
- Functional genomics
-
Indications
-
- Cardiovasculare diseases
- Immunology/allergology
- Oncology
-
Scope of collaboration
-
- Product
- License
- Venture Capital
-
Request
-
- Anti-infective agents
- Pulmonary diseases
- Oncology
- Cardiovascular diseases
- Metabolism
- CNS
-
Contact
-
Hans Wormann
Director External Affairs & Partnerships
Telephone: +49 2137 955-200
Telefax: +49 2137 955-949
-
Scope of collaboration
-
- Product
- License
- Distribution
- Strategic Alliances
-
Offer
-
- Clinical Development
- Licensing
- Marketing & Distribution
-
Request
-
- Therapeutics/diagnostics phase II and III
-
Indications
-
- Anti- infective
- Pulmonary diseases
- Dermatology
- Diabetes
- Cardiovascular diseases
- Nephrology
- Oncology
- Pain
- Virology
- CNS
-
Contact
-
Dr. Karl-Heinz Bajorat
Manager Business Development
Telephone: +49 4864 100-313
Telefax: +49 4864 100-350
-
Scope of collaboration
-
- Development
- License
- Distribution
- Stategic Alliances
- Shareholding
-
Offer
-
-
Request
-
- Therapeutics/diagnostics of clinical phase I - III
- Technology
- Cell cycling
- Cell therapy
- Cytotoxic agents
- Chemical libraries
- Gene therapy
- Functional genomics
-
Indications
-
- Endocrinology
- Cardiovascular diseases
- Oncology
- Urology
- CNS
-
Contact
-
Sandra von Meier
Senior Manager Business Development
Telephone: +49 89 85653306
Telefax: +49 89 85653330
-
Scope of collaboration
-
- Development
- Technology
- Product
- Licence
- Distribution
-
Offer
-
-
Indications
-
-
Contact
-
Ulrike Kluge
Head Business Development Pharmaceuticals
Telephone: +49 1503 213
Telefax: +49 1503 400
-
Scope of collaboration
-
- Development
- Project
- Technology
- Product
- License
- Distribution
- Strategic alliances
- Shareholding
-
Offer
-
- Product development
- Formulation development
- Clinical development
- Regulatory affairs
- Marketing & distribution
-
Request
-
- Products
- Therapeutics/diagnostics from pre-clinical phase I-III
- Drug discovery
- Chemical libraries
- Formulation development
- Small molecules
- Target search
-
Indications
-
- Alzheimer´s disease
- Dermatology
- Musculoskeletal disorders
- Pain
- Orphan diseases
- CNS
-
Contact
-
Dr. Barbara Krebs-Pohl
Head of Business Development
Telephone: +49 89 89927-453
Telefax: +49 89 89927-5453
-
Scope of collaboration
-
- Development
- Technology
- Product
- Licence
- Strategic alliances
-
Offer
-
- Product development
- Clinical development
- Licensing
-
Request
-
- Therapeutics/diagnostics from
- Pre-clinical
- Clinical phase I
- Drug discovery
- Angiogenesis
- Cytokines
- Target search
- Antibodies
-
Contact
-
Sven Werner
Head Business Development & Licensing
Telephone: +49 911 27312-688
Telefax: +49 911 27312-816
-
Scope of collaboration
-
- Development
- Product
- License
- Distribution
- Shareholding
-
Indications
-
- Please see et www.novartis.com
-
Scope of collaboration
-
- Development project
- Research project
- Product
- Licence
- Strategic alliances
-
Offer
-
- Clinical development
- Licensing
-
Request
-
- Products
- Therapeutics/diagnostics from pre-clinic, phase I, phase II,
- Production
- Production of recombinant proteins
- Small molecules
-
Indications
-
- Anaesthesia
- Pain
- CNS
- Orphan diseases
-
Contact
-
Dr. Susanne Schmidt
Director Business Development
Telephone: +49 30 550055-52466
Telefax: +49 30 550054-52466
-
Scope of collaboration
-
- Licensing
- Strategic alliances
-
Contact
-
Dr. Goetz Baumann
Head Future Product Development
Telephone: +49 7624 14-3856
Telefax: +49 7624 5436
-
Scope of collaboration
-
- Development
- Project
- Product
- Licence
- Distribution
- Strategic alliances
-
Offer
-
- Product development
- Clinical development
- Product sales
- Licensing
-
Request
-
- Products
- Therapeutics/diagnostics pre-clinical phase, phase I - III
- In-vitro diagnostics
- Drug discovery
- Angiogenesis
- Cell cycling
- Samll molecules
- Target search
- Phamacogenetics
-
Indications
-
- Alzheimer
- Diagnostics
- Gynaecology
- Immonolgy/allergology
- Oncology
- Gastroenterology/metabolism
- CNS
- Further: anti-HCV, autoimmune disease
Informations about the Biotech-Partnering of Roche Diagnostics GmbH you can findhere.
-
Scope of collaboration
-
- Development
- Project
- Technology
- Product
- Licence
- Strategic Alliances
-
Offer
-
- Product development
- Formulation development
- Clinical development
- Drug Regulatory Affairs
- Licensing
-
Request
-
- Products
- Therapeutics/diagnostics from pre clinical, clinical phase I - III
- In-vitro-diagnostics
- Technology
- HT-Screening
- Protein resp. RNAi based development candidates & technology
- Drug discovery
- Angiogenesis
- Cell therapy
- Cytotoxic agents
- Cytokines
- Chemical libraries
- Gene therapy
- Formulation development
- Functional genomics
- Small molecules
- Target search
- Pharmacogenetics
-
Contact
-
Dr. Paul Rounding
Head of Business Development
Telephone: +49 221 96453-19
Telefax: +49 221 96453-21
-
Offer
-
- Generation of innovative mouse models for pharma research
-
Request
-
- Technology: Mouse models: RNAi, Knockout/knockin, humanization, disease models
-
Contact
-
Dr. Dirk Pelster
Chief Operating Officer
Telephone: +49 89 324266800
Telefax: +49 89 324266899
-
Scope of collaboration
-
- Research project
- Development project
- Technology
- Product
- Licence
- Strategic alliances
-
Offer
-
- Product development
- Formulation development
- Production
- Clinical development
- Drug Regulatory
- Licensing
-
Indications
-
- Immunology/allergology
- Oncology
-
Contact
-
Willy Cnops
Managing Director
Telephone: +49 2173 482333
Telefax: +49 2173 481032
-
Scope of collaboration
-
- Research project
- Development project
- Technology
- Product
- Licence
- Distribution
- Strategic alliances
- Shareholding
-
Offer
-
- Licensing
- Marketing & distribution
-
Request
-
- Products
- Therapeutics/diagnostics from pre-clinical to phase III
- In-vitro-diagnostics
- Drug Discovery
- Angiogenesis
- Cell cycling
- Cell therapy
- Cytotoxic agents
- Cytokines
- Chemical libraries
- Gene therapy
- Formulation development
- Functional genomics
- Small molecules
- Target search
- Pharmacogenetics
- Further: biopharmaceuticals
-
Indications
-
- Allergology
- Alzheimer's
- Pulmonary diseases
- Diagnostics
- Dermatology
- Endocrinology
- Gynaecology
- Cardiovasculare diseases
- Immunology/allergology
- Musculoskeletal disorders
- Nephrology
- Oncology
- Paediatrics
- Pain
- CNS
- Further: internal medicine
Suggest page
Print page
Bookmark page